Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KYAT1 | Q16773 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23354674 | 1.00 | GAA (0.59) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL23354676 | 1.00 | GAA (0.59) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL23354735 | 0.88 | KYAT1 (0.56) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL23354736 | 0.88 | KYAT1 (0.56) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL23367209 | 0.88 | KYAT1 (0.56) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL23367355 | 0.87 | GAA (0.58) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL18121576 | 0.87 | GAA (0.58) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL23354799 | 0.86 | MAPT (0.47) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL23354801 | 0.86 | MAPT (0.47) | GAALMNAALDH1A1NPSR1HPGD | |
| SCHEMBL23367546 | 0.86 | MEN1 (0.60) | GAALMNAALDH1A1NPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | GAA 1454/4885LMNA 2772/4885ALDH1A1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.